Abstract:Backgroud: Controversies exist in choosing Intratympanic gentamicin or intratympanic glucocorticoids for Ménière’s disease. Methods: To assess the treatment effects and safety among intratympanic gentamicin, glucocorticoids and placebo therapy in Ménière disease. Electronic searches in PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, MEDLINE, BIOSIS Previews, Embase, CINAHL, ClinicalTrials.gov and the European Union Clinical Trials Register were conducted from inception until March 2019. All randomized controlled trials of intratympanic gentamicin or glucocorticoids for Ménière’s disease, compared with each other or placebo therapy, were considered for this review. Two independent reviewers extracted study data and performed quality assessment using the Cochrane Risk of Bias Tool. Network meta-analysis on vertigo control, function level scales (FLS), hearing outcomes and tinnitus handicap inventory (THI) were calculated with a Bayesian approach using the R package netmeta (version:3.5.2). The quality of primary outcomes was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Findings: 10 studies of RCTs (455 patients) met inclusion criteria as described. Pooled results indicated significant advantage of intratympanic gentamicin and glucocorticoids over placebo treatments in vertigo control (gentamicin vs placebo: risk rate, RR, 2.56; 95%CI, 1.18 to 5.54; glucocorticoids vs placebo: RR, 3.02; 95%CI, 1.36 to 6.73). The comparison between gentamicin and glucocorticoids did not show a statistically significant result (RR 0.85; 95%CI, 0.69 to 1.03). FLS also showed improvements in intratympanic therapies over placebo. For PTA and SDS, intratympanic glucocorticoids showed better hearing protective results than gentamicin (change of PTA, MD, -6.48 dB; 95%CI, -11.84 dB to -1.13 dB; change of SDS, MD 7.69%; 95%CI, 0.83% to 14.55%),but no statistical significance in comparisons with placebo. No difference was found in THI among three approaches. Interpretation: Intratympanic gentamicin and glucocorticoids are two effective approaches to control vertigo symptoms for Ménière’s disease. Compared with gentamicin, glucocorticoids showed a potentially better hearing protective role, and intratympanic gentamicin therapy was not associated with high risk of hearing loss than placebo.Funding Statement: The authors have no funding to disclose.Declaration of Interests: The authors have no financial relationships, or conflicts of interest to disclose.Ethics Approval Statement: This research was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions, and the PRISMA extension statement for reporting of systematic reviews incorporating NMA of health care interventions. The pre-specified protocol of this systematic review has been registered in November 2018 (PROSPERO Identifier: CRD42018114389).

A Randomised Controlled Trial Comparing Intratympanic Gentamicin with Methylprednisolone in Meniere's Disease with Good Hearing

Comparative efficacy of intratympanic gentamicin and intratympanic corticosteroid in the treatment of Meniere's disease: a systematic review and meta-analysis

Comparative efficacy of intratympanic gentamicin and intratympanic corticosteroid in the treatment of Meniere’s disease: a systematic review and meta-analysis

Effects of Intratympanic Gentamicin and Intratympanic Glucocorticoids in Ménière’s Disease: A Network Meta-Analysis of Randomized, Controlled Trials

Pharmacological Interventions for Menière's Disease: A Systematic Review and Network Meta-Analysis

Effects of intratympanic gentamicin and intratympanic glucocorticoids in Ménière’s disease: a network meta-analysis

Efficacy and Durability of Intratympanic Gentamicin Treatment for Meniere's Disease

[The Effects of Small Dose of Intratympanic Gentamicin Injection on Intractable Meniere's Disease].

Intratympanic Gentamicin Injection for Refractory Ménière's Disease (MD) Has Potential Effect in Preventing Contralateral MD Occurrence

End-point Indicators of Low-Dose Intra-Tympanic Gentamicin in Management of Ménière’s Disease

Long-term effects of intratympanic methylprednisolone perfusion treatment on intractable Ménière's disease.

Modified titration intratympanic gentamicin injection for unilateral intractable Ménière's disease

The effectiveness of intratympanic injections with methylPREDnisolon versus placebo in the treatment of vertigo attacks in MENieres disease (PREDMEN trial): a study protocol for a phase-3 multicentre, double-blinded, randomised, placebo-controlled trial

Intratympanic Gentamycin for Intractable Meniere Disease

Clinical Evaluation of Intratympanic Methylprednisolone Perfusion for Intractable Meniere's Disease

Role of prior intratympanic gentamicin and corticosteroids therapy on speech understanding in patients with Menière's disease after cochlear implantation

Intratympanic dexamethasone and hyaluronic acid in patients with low-frequency and Ménière's-associated sudden sensorineural hearing loss

Consensus on Intra Tympanic Drug Delivery for Menière's Disease

Long-term efficacy of dexamethasone treatment via tympanic antrum catheterization for intractable Meniere's disease

Preclinical and Clinical Studies of Unrelieved Aural Fullness Following Intratympanic Gentamicin Injection in Patients with Intractable Ménière's Disease.

Intratympanic methylprednisolone acetate versus intratympanic lidocaine in the treatment of idiopathic subjective unilateral tinnitus of less than 1-year duration: a randomized, double-blind, clinical trial